Liquid Biopsies in Endocrine Neoplasia—A Systematic Review

Tonozzi, Theresa R.; Kammesheidt, Anja; Braunstein, Glenn D.; researcher, Independent

doi:10.17925/use.2019.15.1.39

Cited by 1 publication

(2 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Limited evidence suggests that the number of circulating tumor cells correlates with initial tumor stage, and also acts as a predictor of recurrence, metastasis, and overall survival, although no definite cut-off values have been established. Attempts have also been made to test the utility of a decrease in circulating tumor cell count to predict response to RAI, but with inconclusive results [ 121 ].…”

Section: Liquid Biopsymentioning

confidence: 99%

“…Thus, liquid biopsy cannot yet replace tissue evaluation in endocrine tumors. It can, instead, be used for follow-up after the identification of specific mutations in the tissue [ 121 ]. Sato [ 122 ], in a recent study on 22 cases of PTC, concluded that BRAF V600E, when detected in pre-surgery plasma is indicative of a high fraction of BRAF V600E in the tumor, and extrathyroidal extension.…”

Section: Liquid Biopsymentioning

confidence: 99%

See 1 more Smart Citation

Emerging Biomarkers in Thyroid Practice and Research

Agarwal

Bychkov

Jung

2021

Cancers

View full text Add to dashboard Cite

Thyroid cancer is the most common endocrine malignancy. Recent developments in molecular biological techniques have led to a better understanding of the pathogenesis and clinical behavior of thyroid neoplasms. This has culminated in the updating of thyroid tumor classification, including the re-categorization of existing and introduction of new entities. In this review, we discuss various molecular biomarkers possessing diagnostic, prognostic, predictive and therapeutic roles in thyroid cancer. A comprehensive account of epigenetic dysregulation, including DNA methylation, the function of various microRNAs and long non-coding RNAs, germline mutations determining familial occurrence of medullary and non-medullary thyroid carcinoma, and single nucleotide polymorphisms predisposed to thyroid tumorigenesis has been provided. In addition to novel immunohistochemical markers, including those for neuroendocrine differentiation, and next-generation immunohistochemistry (BRAF V600E, RAS, TRK, and ALK), the relevance of well-established markers, such as Ki-67, in current clinical practice has also been discussed. A tumor microenvironment (PD-L1, CD markers) and its influence in predicting responses to immunotherapy in thyroid cancer and the expanding arena of techniques, including liquid biopsy based on circulating nucleic acids and plasma-derived exosomes as a non-invasive technique for patient management, are also summarized.

show abstract

Section: Liquid Biopsymentioning

confidence: 99%

Section: Liquid Biopsymentioning

confidence: 99%